semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss GLP-1 agonists like Ozempic may

GLP1 therapies primarily target hunger and appetite, but those arent the only factors that influence weight

In Phase 2 substudies, Retatrutide cleared an astonishing amount of excess liver fat

Results from such research do not constitute evidence that any specific finished product will produce particular outcomes in individuals

No over-reporting of suicide/self-injury was identified for GLP-1RA before or after the COVID-19 pandemic outbreak

Current evidence suggests there may be a link between GLP-1 medications and hair loss, particularly with semaglutide (Wegovy) and tirzepatide (Mounjaro), but researchers have not proven that the medication itself directly causes hair loss